行情

AGRX

AGRX

Agile
NASDAQ

实时行情|Nasdaq Last Sale

3.350
+0.270
+8.77%
盘后: 3.300 -0.05 -1.49% 19:31 01/24 EST
开盘
3.140
昨收
3.080
最高
3.580
最低
3.140
成交量
650.90万
成交额
--
52周最高
3.580
52周最低
0.3500
市值
1.99亿
市盈率(TTM)
-8.4129
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

AGRX 新闻

  • Comcast: 5%+ Correction Post Q4 Results Not Justified: Reiterate Buy
  • Seeking Alpha - Article.12小时前
  • Comcast -1.2% as UBS sees investments weighing growth
  • Seeking Alpha - Article.19小时前
  • Here are the biggest analyst calls of the day: Alphabet, Apple, PayPal, Intel & more
  • CNBC.com.19小时前
  • ClearBridge Multi Cap Growth Strategy Portfolio Manager Commentary Q4 2019
  • Seeking Alpha - Article.21小时前

更多

所属板块

制药
-1.84%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

AGRX 简况

Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
展开

Webull提供Agile Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。